Re-optimization Based Online Adaptive Radiotherapy of Anal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHerlev Hospital
About this trial
A single-arm, prospective, Phase II, single-center clinical trial that will investigate if daily online adaptive radiotherapy for anal cancer will significantly reduce early treatment-related GI toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Eligibility criteria
Qualifiers
Biopsy-verified anal cancer
Eligible for curative intended radiotherapy
Written and oral consent
Disqualifiers
Other malignant disease within the past 5 years (excluding basal cell carcinoma)
Trial design
Treatments tested in this trial
- online adaptive radiotherapy
Treatment groups
205 Participants
are divided into 1 treatment groupLocations
1Oncology dept, Herlev and Gentofte Hospital2730, Herlev Denmark
Sponsors and collaborators
Herlev Hospital
Lead sponsor
Source ClinicalTrials.gov